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Uveal melanoma (UM) is the most common intraocular malignancy in adults. The lack of an 
effective treatment results in a median survival time of less than one year for patients with 
metastatic disease and shows the high unmet need for the development of effective 
treatments. Recently, the melanoma-specific lncRNA SAMMSON was shown to be essential 
for skin melanoma survival. Analysis of a PAN cancer RNA-sequencing dataset revealed 
consistent expression of SAMMSON in uveal melanoma tumors. Targeting SAMMSON by 
means of antisense oligonucleotides (ASOs) results in a strong reduction in cell viability with 
induction of apoptosis of UM cells and slows down tumor growth in multiple UM PDX models. 
These effects were driven by impaired mitochondrial function and protein translation, 
resulting in cell death. To identify potential synergistic combinations, we combined 
SAMMSON knockdown with a library of 2911 FDA-approved drugs and quantified cell viability 
in a uveal melanoma cell line. The strongest synergy was obtained with the mTOR inhibitor 
GDC-0349. Combining SAMMSON knockdown with mTOR inhibition resulted in enhanced 
impairment of mitochondrial function and protein synthesis. Interestingly, we observed a 
more pronounced knockdown of SAMMSON when combining SAMMSON targeting ASOs with 
GDC-0349, suggesting mTOR inhibition facilitates ASO uptake in uveal melanoma cells. 
Further experiments are ongoing to confirm this mechanism. Taken together, these results 
demonstrate that SAMMSON inhibition in combination with mTOR inhibition could be a novel 
treatment option for uveal melanoma patients. 
 
 
 
 
